- Home
- RCMT vs OTLK Comparison
RCMT vs OTLK Comparison
Compare RCMT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCMT | OTLK |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | 4930 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.8M | 249.6M |
| IPO Year | 1997 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RCMT | OTLK |
|---|---|---|
| Price | $42.02 | $0.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $45.00 | $5.03 |
| AVG Volume (30 Days) | 59.8K | ★ 3.4M |
| Earning Date | 11-04-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.38 | ★ 55.91 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $186,737,000.00 | $8,146,123.00 |
| Revenue This Year | $11.47 | N/A |
| Revenue Next Year | $10.09 | $6,355.64 |
| P/E Ratio | $34.21 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $0.16 |
| 52 Week High | $43.09 | $2.54 |
Technical Indicators
Market Signals| Indicator | RCMT | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 31.66 |
| Support Level | $38.84 | $0.50 |
| Resistance Level | $42.54 | $0.72 |
| Average True Range (ATR) | 1.04 | 0.04 |
| MACD | -0.24 | 0.00 |
| Stochastic Oscillator | 58.23 | 0.06 |
Price Performance
Historical ComparisonAbout RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.